Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases

Author(s): Michael J. Schnieders, Tamer S. Kaoud, Chunli Yan, Kevin N. Dalby, Pengyu Ren

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 9 , 2012

Become EABM
Become Reviewer
Call for Editor


Due to their role in cellular signaling mitogen activated protein (MAP) kinases represent targets of pharmaceutical interest. However, the majority of known MAP kinase inhibitors compete with cellular ATP and target an ATP binding pocket that is highly conserved in the 500 plus representatives of the human protein kinase family. Here we review progress toward the development of non-ATP competitive MAP kinase inhibitors for the extracellular signal regulated kinases (ERK1/2), the c-jun N-terminal kinases (JNK1/2/3) and the p38 MAPKs (α, β, γ, and δ). Special emphasis is placed on the role of computational methods in the drug discovery process for MAP kinases. Topics include recent advances in X-ray crystallography theory that improve the MAP kinase structures essential to structurebased drug discovery, the use of molecular dynamics to understand the conformational heterogeneity of the activation loop and inhibitors discovered by virtual screening. The impact of an advanced polarizable force field such as AMOEBA used in conjunction with sophisticated kinetic and thermodynamic simulation methods is also discussed.

Keywords: Kinases, MAP, modeling, dynamics, non-ATP, inhibitor

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 01 March, 2012
Page: [1173 - 1185]
Pages: 13
DOI: 10.2174/138161212799436368
Price: $65

Article Metrics

PDF: 26